Drugs.com - Pharma Industry News

ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer

THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) yields better event-free survival outcomes than FLOT alone...

Jun 5, 2025 - 18:55
 0
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) yields better event-free survival outcomes than FLOT alone...
Read More

Tags:

Previous Article

Odds of Advanced Cancer, Breast Cancer Death Lower in Screen-Detected Disease

Next Article

Cardiometabolic Risk Factors Account for More Than One-Third of Dementia Risk

Related Posts

Childhood Cancer Survivors Have Increased Risk for CKD, Hypertension

Childhood Cancer Survivors Have Increased Risk for CKD,...

May 22, 2025  0

Parent-Mediated Intervention Beneficial for Toddlers Who Are Deaf

Parent-Mediated Intervention Beneficial for Toddlers Wh...

May 28, 2025  0

Vitamin D3 Supplementation Reduces Telomere Attrition

Vitamin D3 Supplementation Reduces Telomere Attrition

Jun 2, 2025  0